TKNOAlpha Teknova, Inc.

$133M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$8M-0.3% YoY

Gross Profit

$1M17.0% margin

Operating Income

-$11M-138.0% margin

Net Income

-$11M-135.5% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-3.7%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$129M

Total Liabilities

$39M

Stockholders' Equity

$90M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$8M	-0.3%
Gross Profit	$1M	$2M	-36.7%
Operating Income	-$11M	-$14M	+23.7%
Net Income	-$11M	-$13M	+19.8%

Revenue Segments

Lab Essentials

$7M85%

Clinical Solutions

$879,00011%

Other Product

$300,0004%

Geographic Segments

UNITED STATES

$7M94%

Non-US

$495,0006%

TKNO Q4 2023 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena